A clinical trial involving oxytocin as a comparator context reached completed status as of August 6, 2026. The study, registered as NCT06970483, is titled "Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery." It is listed as a Phase 4 trial.
The trial evaluated misoprostol and tranexamic acid for use in preventing postpartum hemorrhage during cesarean delivery. Oxytocin, an approved compound, is commonly referenced in this clinical context as a standard prophylactic agent. The trial record indicates a status of completed, with no additional outcome data provided in this update.
No results have been reported alongside this status change. This brief reflects only the trial's title, phase, and completion status as recorded on ClinicalTrials.gov. No efficacy or safety conclusions can be drawn from a completion status alone, since detailed results are not included in this update.
Readers interested in oxytocin's approved uses and background can consult the compound overview for further context.